GGiantBullStocks

Tyra Biosciences, Inc. (TYRA)

NASDAQ · Healthcare

$31.06-3.35%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$1.95B
P/E ratio
EPS
Volume
342,579
52-week high
52-week low
Open
$32.05
Day high
$33.05
Day low
$31.03

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025-$119.95M-$2.01
2024-$86.48M-$1.51
2023-$69.13M-$1.62
2022-$55.33M-$1.32
2021-$26.29M-$1.91

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

CEO
Todd Harris
Employees
87
Country
US
IPO date
Sep 15, 2021

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Tyra Biosciences, Inc.'s stock price today?
TYRA is trading at $31.06 as of Jul 20, 2026.
What is Tyra Biosciences, Inc.'s market cap?
Tyra Biosciences, Inc. (TYRA) has a market capitalization of $1.95B.
Does Tyra Biosciences, Inc. pay a dividend?
Tyra Biosciences, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Tyra Biosciences, Inc. in?
Tyra Biosciences, Inc. operates in the Healthcare sector.